Invicta Launches First Licensed Medicine - POM-V Product, SynVet-50

Invicta Animal Health has launched its’ first POM-V product, SynVet-50. The product is a licensed synthetic Sodium Hyaluronate (HA), for intra-articular treatment of lameness caused by joint dysfunction associated with non-infectious synovitis in horses. The functional mechanisms of HA are directly dependent on the molecular weight and concentration of HA. ¹ Therefore, SynVet-50 has been formulated with a molecular weight of 1.5m Daltons which is the highest of any synthetic HA available in the UK. Additionally, at 20mg per ml, SynVet-50 is also the most concentrated HA available. Storage is at ambient temperature so the product is not subject to refrigerated storage. SynVet-50 is a 2.5ml solution containing 50mg HA, conveniently presented in a 5ml glass syringe. Rob Watkins, Managing Director of Invicta said “We are excited to be launching our first licensed medicine in the UK. The management team of Invicta have over 10 years experience in this market which has allowed us to provide a product strongly focussed on the clinicians needs, not just in terms of technical ability, but also in convenience of presentation”. For further information see www.invictavet.com or phone 01403 791313 ^1. Dr. Lisa A. Fortier (2011), Lameness: Medicating/Treating the competition horse, Proceedings of the BEVA congress, September 7-10, 2011, Liverpool, p110-111

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards